One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
Neumora Therapeutics, Inc.
NMRA · NMS · Healthcare · Biotechnology
Current price
$0.39
52-week range
$0.32 - $3.65
Market cap
$73.82M
Balance sheet
Healthy
-74.92x Concerning
Net cash $63.58M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
1 Risk
0 rewards · 1 risks
View details ↓What this company does
Neumora Therapeutics, Inc.
Neumora Therapeutics is a company working on new medicines for brain conditions like depression and Alzheimer's disease. They primarily make money from investments and grants as they are still developing their treatments, not selling them yet, which means their financial success hinges on these experimental drugs proving effective in human trials.
How the company got here
Neumora Therapeutics, Inc. was founded in 2019, initially known as RBNC Therapeutics, Inc., and rebranded to Neumora in October 2021. The company is a clinical-stage biopharmaceutical firm focused on creating new medicines for brain-related conditions. Its journey began with a clear mission to address significant unmet needs in the treatment of neurological and psychiatric disorders. The company's progress is marked by its advancement of several drug candidates through various stages of clinical trials, aiming to bring innovative therapies to patients.
What it actually does
Neumora Therapeutics is dedicated to developing treatments for a range of brain diseases, including neuropsychiatric disorders (like depression and schizophrenia) and neurodegenerative diseases (such as Alzheimer's and Parkinson's). They are not selling any products yet, as their focus is on researching and testing potential new medicines in clinical trials. These trials are crucial steps to determine if a drug is safe and effective for people before it can be approved for widespread use.
Pipeline of Potential Treatments
Neumora's core business revolves around its pipeline of drug candidates, each targeting different brain conditions. Their most advanced candidate, navacaprant, is a potential treatment for major depressive disorder and is currently in Phase 3 clinical trials, which are the final stage of testing before seeking regulatory approval. Other candidates, like NMRA-511 for agitation in Alzheimer's patients and NMRA-861/898 for schizophrenia, are in earlier stages of development (Phase 1b and preclinical). The company is also exploring treatments for Parkinson's Disease, Amyotrophic Lateral Sclerosis (ALS), and obesity through various research programs.
What management is betting on now
The company's primary strategic focus is on advancing its most promising drug candidates through the rigorous clinical trial process. Management is heavily invested in successfully completing Phase 3 trials for navacaprant, as a positive outcome could lead to a significant new treatment option for major depressive disorder. Simultaneously, they are pushing forward with the development of other pipeline assets targeting different neurological and psychiatric conditions. This strategy hinges on demonstrating the safety and efficacy of their novel therapeutic approaches to ultimately gain regulatory approval and bring these much-needed medicines to market.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$-33.48M
FY2025 Q3
$-46.65M
Revenue
—
Net income
$-43.08M
Diluted EPS
-0.23
Operating cash flow
$-39.53M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-53.46M
Diluted EPS
-0.30
Operating cash flow
$-46.40M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-59.45M
Diluted EPS
-0.35
Operating cash flow
$-47.95M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-56.76M
Diluted EPS
-0.35
Operating cash flow
$-46.63M
Free cash flow
$-46.65M
Fetching…
Sources
Revenue
—
Net income
$-52.73M
Diluted EPS
-0.33
Operating cash flow
$-52.40M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-67.99M
Diluted EPS
-0.42
Operating cash flow
$-59.45M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-58.82M
Diluted EPS
-0.37
Operating cash flow
$-50.34M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-72.55M
Diluted EPS
-0.45
Operating cash flow
$-33.48M
Free cash flow
$-33.48M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $0.39
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $63.6M - more cash than debt. Interest coverage -74.9x.
Net debt
$-63.58M
Interest coverage
-74.92x
Neumora Therapeutics, Inc.'s profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here.
Healthy
Worse cushion
Baseline
Better cushion
NMRA
BASELINE
Neumora Therapeutics, Inc.
Total debt $53.25M Interest coverage -74.92x This is the baseline the peer rows are being compared against.
Total debt $2.71B Interest coverage 84.52x This peer still has a real interest-payment cushion, while NMRA does not.
Total debt $8.36B Interest coverage 9.23x This peer still has a real interest-payment cushion, while NMRA does not.
Total debt $26.25B Interest coverage 11.43x This peer still has a real interest-payment cushion, while NMRA does not.
Total debt $1.98B Interest coverage 342.44x This peer still has a real interest-payment cushion, while NMRA does not.
Total debt $32.35B Interest coverage 8.26x This peer still has a real interest-payment cushion, while NMRA does not.
What you should know
The case for and against NMRA
0 Rewards
1 Risk
Rewards
Risks
-
Return on equity was -187.1% last year — the company lost money on shareholders' equity.
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-0.59x
P/B
1.65x
P/S
—
EV/EBITDA
-0.04x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
-187.1%
ROA
-73.9%
Health
Liquidity and balance-sheet strength
Debt / equity
1.20x
Current ratio
4.50x
Quick ratio
4.21x
Total debt
$53.25M
Total cash
$116.83M
Growth
How the business has been compounding
Revenue TTM
$0.00
Revenue 5Y CAGR
—
EPS TTM
-1.23
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-180.52M
Free CF TTM
$-206.44M
FCF margin
—
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
—
Last ex-div date
—